MNCs Can Access Asian Markets Faster With Bridging Studies – Parexel Exec
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Global studies that include Asia should be part of any multinational company's strategy to accelerate development time and gain access to the Asian market, a Parexel exec told the recent BioMedical Asia conference in Singapore
You may also be interested in...
Japanese, Chinese Regulators Step Up Communications To Increase Effectiveness, Speed Up Approval - DIA China Conference
BEIJING - Communication with regulators is essential for clinical development success and increasingly drug companies are engaging with multiple regulators simultaneously along parallel tracks; regulators are responding in some surprising ways that show they are willing to change, leaders from China and Japan told scientists and executives at the China Drug Information Association meeting in Beijing May 18
Japanese, Chinese Regulators Step Up Communications To Increase Effectiveness, Speed Up Approval - DIA China Conference
BEIJING - Communication with regulators is essential for clinical development success and increasingly drug companies are engaging with multiple regulators simultaneously along parallel tracks; regulators are responding in some surprising ways that show they are willing to change, leaders from China and Japan told scientists and executives at the China Drug Information Association meeting in Beijing May 18
Charles River, Parexel, PPD: PharmAsia News CRO Earnings Roundup
The largest contract research organizations have begun to spread their reach into emerging markets to keep pace with their big pharma customers